The dilute Russell Viper Venom time integrated test is a sensitive methold for the detection of Lupus Anticoagulants (LA). LA are autoantibodies that target protein-phospholipid complexes and are found in a variety of clinical conditions. In some patients, a confirmed positive result is associated with an increased thrombotic risk, and is often found in women who have recurrent fetal loss. As Lupus anticoagulants reflect a heterogenous group of antibodies, international consensus guidelines on testing require at least two screening assays be used for a complete evaluation. Refer to Lupus Anticoagulant Comprehensive Evaluation which includes the DRVVT plus a second pathway of testing, the PTT-LA with reflex to Hexagonal Phase Confirm and Thrombin Time.
2 - 1.0 mL Frozen Plasma from 2 Blue Top Tubes - 3.2% Na Citrate in a 2 Plastic Vials
Unacceptable Ambient
Unacceptable Refrigerated
90 days Frozen
Freeze immediately and ship on dry ice.
Please submit a separate, frozen vial for each special coagulation assay ordered. Draw blood in a light blue-top tube containing 3.2% sodium citrate, mix gently by inverting 3-4 times. Centrifuge 15 minutes at 1500 g within one hour of collection. Using a plastic pipette, remove plasma, taking care to avoid the WBC/platelet buffy layer and place into a plastic vial. Centrifuge a second time and transfer platelet-poor plasma into a new plastic vial(s). Freeze immediately and transport on dry ice.
Note: the presence of direct oral anticoagulants may interfere with testing.
1.0 mL platelet poor plasma
| dRVVT Screen | ≤45 seconds |
| dRVVT Confirm | Negative |
| dRVVT 1:1 Mix | Corrected |
If dRVVT Screen is prolonged (>45 seconds), then dRVVT Confirm will be performed at an additional charge
If dRVVT Confirm is positive, then dRVVT 1:1 Mixing Study will be performed at an additional charge.
The dilute Russell Viper Venom time integrated test is a sensitive methold for the detection of Lupus Anticoagulants (LA). LA are autoantibodies that target protein-phospholipid complexes and are found in a variety of clinical conditions. In some patients, a confirmed positive result is associated with an increased thrombotic risk, and is often found in women who have recurrent fetal loss. As Lupus anticoagulants reflect a heterogenous group of antibodies, international consensus guidelines on testing require at least two screening assays be used for a complete evaluation. Refer to Lupus Anticoagulant Comprehensive Evaluation which includes the DRVVT plus a second pathway of testing, the PTT-LA with reflex to Hexagonal Phase Confirm and Thrombin Time.
3 to 6 days
85613 (85597, 85613)